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Radiopharmaceuticals are reemerging as attractive anticancer agents, but there are no
universally adopted guidelines or standardized procedures for evaluating agent validity
before early-phase trial implementation. To validate a radiopharmaceutical, it is desirous
for the radiopharmaceutical to be specific, selective, and deliverable against tumors of a
given, molecularly defined cancer for which it is intended to treat. In this article, we discuss
four levels of evidence—target antigen immunohistochemistry, in vitro and in vivo
preclinical experiments, animal biodistribution and dosimetry studies, and first-in-human
microdose biodistribution studies—that might be used to justify oncology therapeutic
radiopharmaceuticals in a drug-development sequence involving early-phase trials. We
discuss common practices for validating radiopharmaceuticals for clinical use, everyday
pitfalls, and commonplace operationalizing steps for radiopharmaceutical early-phase
trials. We anticipate in the near-term that radiopharmaceutical trials will become a larger
proportion of the National Cancer Institute Cancer Therapy Evaluation Program
(CTEP) portfolio.
Keywords: radiopharmaceutical, preclinical, validation, nuclear medicine, radiation oncology
INTRODUCTION
New radiopharmaceuticals intended for clinical use typically follow complex drug-development
sequences that expend considerable resources and time. Many are now molecularly targeted, and
therefore, might only benefit a subgroup of cancer patients whose tumors express specific targets.
Conventional drug-development sequences, which focus on preclinical in vitro and in vivo studies
justifying early-phase I or II trials, and then if warranted, late-phase III trials without assessment of
the target expression, are suboptimal in the clinical evaluation of radiopharmaceuticals.
Radiopharmaceutical drug-development sequences therefore might benefit from ‘enrichment’
approaches that more reliably reduce patient resources and shorten trial timelines (1).
Radiopharmaceutical validation might be considered one of those enrichment approaches.
Validation in oncology means a process whereby preclinical or clinical investigations denote
agent performance as being suitable for its intended clinical use (2). For therapeutic
radiopharmaceuticals, that agent should demonstrate specificity, selectivity, and deliverability
against tumors in a cancer patient subgroup likely to benefit from its prescription. Successful
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validation improves efficiency in the drug-development sequence
by increasing predictive power and by shortening timelines
through a fairly small sample size in whom a treatment effect
would be expected to be reasonably large (3).
An example of radiopharmaceutical validation is the drug-
development sequence for high-specific-activity 131I-meta-iodo-
benzylguanidine [iobenguane 131I (Azedra)] (4–7). Meta-iodo-
benzylguanidine (MIBG) is a substrate for a norepinephrine cell
surface transporter among chromaffin cells of pheochromocytomas
or paragangliomas (4). Unlabeled MIBG disrupts norepinephrine
re-uptake, which then disadvantageously lowers tumor uptake of
therapeutic 131I-MIBG and then harmfully elevates circulating
norepinephrine. Elevated circulating norepinephrine induces high-
grade acute hypertension (5, 6). Through improved radiochemistry,
the iobenguane 131I drug product has little to no unlabeled MIBG
(7). Phase I and phase II trials were designed to assess up to two
dosages of iobenguane 131I [500 mCi (or if less than 62.5 kg then 8
mCi kg-1)] in the first-line treatment of patients with MIBG-avid
pheochromocytoma or paraganglioma, with a primary objective of
reduced hypertension (5, 6). In the phase II trial, 25 percent (17 of
68) of patients had reduced use of antihypertensionmedications (6).
This led to regulatory approval of iobenguane 131I in MIBG-avid
pheochromocytoma or paraganglioma patients 12 years or
older (8).
In the National Cancer Institute Cancer Therapy Evaluation
Program (CTEP) drug-development sequence, an enrichment
approach involves biomarker-driven trial designs for the novel
study of radiopharmaceutical agents against cancer. By studying
these agents as drugs from the beginning, CTEP staff have
adopted the view that radiopharmaceuticals can follow a
simpler but leveraged programmatic path for development to
meet unmet cancer patient need. For this article, our thoughts are
framed by the low- and high-specific-activity tin-117m(4+)
diethylenetriaminepentaacetic acid (Sn-117m-DTPA; NSC
824376) radiopharmaceutical, intended first for monotherapy
trial evaluation (NCT04616547), and then, combination agent
trials. Challenges and opportunities for radiopharmaceutical
validation are discussed for Sn-117m-DTPA (created by the
nuclear reaction Sn-117(n,g)Sn-117m; 13.6-day half-life; decays
by conversion electrons of 127-129 and 153 keV and by a 158.6
keV gamma photon) (9–15). Here, we propose a four-step
process for radiopharmaceutical validation for clinical use.
Factors impacting the operationalizing of radiopharmaceutical
trials are also discussed.
CHALLENGES AND OPPORTUNITIES
Recommended Step 1
For an oncology therapeutic radiopharmaceutical, a sponsor should
establish that it is specific, selective, and deliverable against tumors
in a patient subgroup likely to benefit from its administration.
Radiopharmaceuticals are drugs that can be infused, ingested,
inhaled, or injected. They act as drugs to deliver DNA-damaging
radioactivity in the form of alpha-particles (i.e., helium nuclei
emitted from the nuclei of radionuclides), beta-particles (i.e.,
electrons emitted from the nuclei of radionuclides), or conversion
electrons (i.e., electrons emitted from electron shells of
radionuclides) to cancer cells residing in tumors or circulating in
the blood. These drugs are either ‘conjugated’ (i.e., have a ligand-
chelator-payload structure) or “neat” (i.e., payload or chelator-
payload only). The radiopharmaceutical prostate-specific
membrane antigen (PSMA)-targeted thorium-227 conjugate
(PSMA-TTC) fits into the conjugate class, as it is given by vein as
a slow bolus that then tracks to PSMA-expressing tumors with the
aid of the BAY2315493 antibody-chelator ligand (16). In a different
way, the radiopharmaceutical Sn-117m-DTPA falls into the neat
class. It has two components—a radioactive payload and a
radiochemical chelator. Each component adds patient safety risk.
Therefore, CTEP has embraced a strategy for drug-development of
radiopharmaceuticals that evaluates payload, chelator, and any
ligand toxicity prior to embarking on trials. A first step in this
strategy is to consider radiopharmaceutical specificity by target
antigen immunohistochemistry (IHC) or by microautoradiography.
Although radiopharmaceutical working groups have enunciated
the need, there are no universally adopted guidelines for best
practice in determining radiopharmaceutical specificity. The
broad variability in investigational zeal and in scientific method
for what is used to test radiopharmaceutical specificity is likely
responsible for a lack of consensus on a single validation strategy. In
our view, the first step should be an IHC assessment of the intended
antigen or radiochemical target on formalin-fixed paraffin
embedded (FFPE) tissues (Figure 1). Our suggested best option
for antigen screen is a tissue microarray (TMA). A TMA is a single
recipient FFPE block created by extracting multiple cylindrical cores
from of interest FFPE donor blocks and re-embedding the cores at
defined array coordinates. Several hundred tissue cores can be
arrayed into a single FFPE TMA. For a conjugated oncology
therapeutic radiopharmaceutical, the nonradioactive ligand-
chelator can assay TMA tissue expressing or not expressing the
intended cancer cell antigen target. If the ligand-chelator is specific,
the IHC stain will be intensely positive on the of interest cancer
tissue and null or weakly positive on nontargeted tissue. PSMA-
TTC preclinical evaluation is an example where IHC showed target
engagement in prostate cancer tumors (16). For a chelator-payload
only construct, the IHC method for radiopharmaceutical validation
is more challenging. It is most often modelled by postmortem
autopsy with scintigrams or microautoradiography. An example
using this technique was published for the validation of Sn-117m-
DTPA (11). Photography, scintigraphy, and undecalcified
microautoradiography showed 47-day posttherapy Sn-117m-
DTPA localization of the radiopharmaceutical in mineralizing
osteoid interfaces of the thoracolumbar spine from a 64-year-old
man with advanced-stage metastatic prostate adenocarcinoma
who underwent autopsy 6 h after death (11). Pitfalls to a
microautoradiography technique include antigen variability by
time to fixation, inadequate fixation period, difference in
embalming fixatives, and logistics of calcified/decalcified tissue
processing. For these reasons, an appropriately designed TMA, in
our opinion, is optimal for antigen screening.
A key to establishing radiopharmaceutical specificity using a
TMA is often the correct use of controls. A best-practice negative
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control is a cell line or tissue that is known not to express the
radiopharmaceutical target of interest. Antigen knockout cells,
proliferated in vitro, pelleted, and then FFPE-cored for the TMA,
provide the best negative controls. Antigen nonexpressing cells
that are then transfected with the target antigen of interest offer
the best positive controls. Given that such cell lines are often
beyond the reach of radiobiological laboratories, there are other
approaches that can be used to acquire comparable TMA control
results. One alternative to antigen knockout cell controls is the use
of siRNA or shRNA knockdown cell controls. Another option is to
array three or more of interest cancer tissue cores from different
patient samples, and then, add at least two corresponding organ
normal tissue cores. If the radiopharmaceutical is specific, the IHC
stain will be intensely positive on the cancer tissue of interest and
null or weakly positive on nontargeted normal tissues in the TMA.
Random selection of FFPE donor blocks missing antigen
expression, and, antigen heterogeneity are recognized drawbacks
of this option, but the cancer core TMA technique was useful in
predicting response in uterine cervix cancer (17, 18). A good
radiopharmaceutical ligand antigen will have the following
characteristics—i) it will bind by IHC to the cancer cell pellets
expressing the target antigen, ii) its staining intensity will decrease
with increasing dilutions of the IHC ligand, and iii) it will
demonstrate an expression pattern among IHC tissues in
concordance with biological and mechanistic data.
Our first proposed validation step is relatively quick, inexpensive,
and mostly comprehensive. It uses a hierarchy of evidence common
in antibody validation (19). While additional research is needed, the
demonstration that a radiopharmaceutical is specific, selective, and
deliverable against tumors in a patient subgroup likely to benefit
from its administration remains essential in the critical evaluation of
oncology therapeutic radiopharmaceuticals intended for clinical use.
Recommendation Step 2
Early-phase oncology therapeutic radiopharmaceutical trials should
state a clear, detailed hypothesis, providing pharmacologic or
biologic rationale inclusive of at least two cancer models each of
in vitro and in vivo data.
Given that a vast number of radiopharmaceuticals might be
evaluated alone or in combination, priority should be given to
those that are associated with well-characterized molecular
targets, strong mechanistic rationale, and high likelihood for
therapeutic success (18). But the level of preclinical data needed
to predict therapeutic success in radiopharmaceutical trials is
currently unknown (19). Radiobiology in vitro and in vivo
experiments do aid in prioritization of radiopharmaceuticals
and their combination partners, and therefore, contribute to
the design of biomarker-driven clinical trials (Figure 1). We do
recognize that there is an evolving use of two-dimensional cell
culture (2D) and three-dimensional organoid coculture (3D)
model systems, and so, we are reluctant to be authoritative on the
modern complexities of radiobiological science. A general
preclinical approach might be as follows (20, 21).
First, 2D and now preferably 3D in vitro cultures should
involve clinically-relevant concentrations and exposures of
radiopharmaceuticals alone, or, in combination with oncologic
agents. Two cancer cell lines of interest are recommended for in vitro
experimentation (i.e., two prostate cancer cell lines for a prostate
cancer trial proposal) and data should not be extrapolated from
A B
C D
FIGURE 1 | Hierarchy of evidence to justify radiopharmaceutical target-driven early-phase combination trial designs. (A) Step 1 of radiopharmaceutical target
validation uses tissue microarray (TMA) immunohistochemistry to distinguish tumor antigens of interest from amongst positive and negative controls. (B) Step 2
involves two in vitro cell survival experiments followed by two in vivo tumor growth delay experiments in animal models [e.g., zebrafish (Danio rerio) or mouse (Mus
musculus)]. (C) Step 3 is a single rodent or nonrodent species biodistribution study for pharmacokinetics and dosimetry. (D) Step 4 is a first-in-human radiation/
nuclear medicine imaging experience that precedes early-phase or late phase clinical development. Sample size (N) represents estimated cohort sizes.
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unrelated cell lines (20). Cell-derived or patient-derived organoid
models might best approximatemicroenvironmental, oxygenation, or
spatiotemporal heterogeneity factors relevant for radiopharmaceutical
radiosensitivity (21). We do contend that the actual in vitrometabolic
or clonogenic survival techniques could vary in this step to assess
activity, or here meaning cytotoxic effect size (20). But we advocate
that any metabolic cytotoxic “hit” should be confirmed by a
clonogenic survival assay, as the latter measures three-to-four logs
of cell kill and not just metabolic growth arrest (20, 21). This step
might also include assessing activity against radiopharmaceutical and
oncologic agent timing (i.e., oncologic agent exposure 1-h before or 1-
h after the radiopharmaceutical exposure) or sequence (i.e.,
radiopharmaceutical first then oncologic agent or the reverse).
Here, there is an opportunity for innovation whereby an in vitro
cell incubator with microfluidic channels for radiopharmaceutical
delivery could be manufactured [as was done for low-dose-rate
brachytherapy (22)] for experimentation rather than use the usual
external beam radiotherapy in vitro technique. So overall, we view the
first preclinical step as a way to narrow down effective dosages and
schedules that will undergo animal model testing. When radioactive
dosage and schedule are known in general due to parameters set forth
from investigational new drug (IND)-enabling toxicology studies,
sponsors might just jump to testing in vertebrate models.
Second, the evaluation of in vivo efficacy in vertebrate models for
treatment exposures that are relevant in the clinic comes next. Tumor
growth delay assays score in vivo efficacy by plotting tumor size versus
dose to assesses radiopharmaceutical-agent interaction,
microenvironment, oxygenation, or spatiotemporal heterogeneity
factors (21). We recommend at least two cell-derived or patient-
derived in vivomodels for initial study, best represented by xenografts
derived from cancer cells of interest carried forward from in vitro
experiments (20, 21). A challenge here is whether tumor shrinkage or
growth in the vertebrate model system actually predicts human
tumor control (21). Take Sn-117m preclinical development (9, 10),
where chelators for the Sn-117m were chloride, pyrophosphate,
ethyldenehydroxy disodium phosphonate, methylene
diphosphonate, or diethylenetriaminepentaacetic acid (DTPA).
These chelators display substantial differences for bone uptake, soft
tissue uptake, blood clearance, and excretion. As kits for technetium
(Tc)-99m diagnostic radiopharmaceutical include milligram
quantities of tin(2+) in its stannous form (9), it did not make sense
to the sponsor to first expend resources and time in an in vitro
radiochemical screen. So, in their in vivo animal studies, a single strain
of Hale-Stoner Brookhaven National Laboratory mice of similar
weight and age were injected in the tail vein with two to five
microcuries of Sn-117m radioactivity for biodistribution and
toxicology studies (9, 10). One mouse experiment involved use of a
human osteogenic sarcoma transplant (10). In brief summary, the
investigators observed a favorable bone-homing feature of the Sn-
117m-DTPA without undue normal organ accumulation or injury
from among the radiochemical chelators. Sn-117m-DTPA was
selected therefore for clinical development (11–15). We suggest that
these Sn-117m-DTPA preclinical studies were mostly comprehensive
in that the in vivo models i) had all the cellular elements of human
tumors (i.e., cancer cells, epithelial and nonepithelial cells, and
vasculature) as well as ii) had agent exposure to vital organs
whereby toxicity could determine the risk-benefit ratio (9, 10).
In general, the second preclinical step justifies dosages and
schedules for in human study under an IND.
Nowadays, we argue that lower vertebrate drug-radiotherapy
screens, such as in zebrafish (23), have utility in agent schedule
and sequence triaging so that only “effective” treatments are
studied in higher vertebrates like rodents, rabbits, or canines.
Zebrafish (Danio rerio) embryos provide an unusual opportunity
to screen drug or radiopharmaceutical agents intended against
cancer because of their close genetic and physiologic homology
to mammals, their rapid and linear embryonic development in
water, their optical clarity allowing inspection of normal organ
differentiation and growth, and aqueous environment receptive
to radiopharmaceutical, radiotherapy, or oncologic drug exposure.
Initial studies associated cytotoxic effect size of radiation response
modifiers on defined zebrafish developmental stages
postfertilization (23). A zebrafish growth delay assay serves as
one example (Figure 2). In our example for three oncology drug
products, there are at least eight treatment groups. Due to their
relatively high clutch size (up to 100 embryos per mating pair)
and short linear 14-day embryo-to-larvae-to-juvenile
development (24, 25), zebrafish can be used quickly to screen
cytotoxic effect size and any unhealthy normal organ toxicity.
Despite over three decades of research, an inexpensive zebrafish
model remains underutilized in oncology drug product
screens prior to rodent or nonrodent pharmacokinetic or
toxicology studies.
Regulatory agency guidelines for higher vertebrate safety
studies involve comprehensive veterinary observations following
radiopharmaceutical dosages in rodents and nonrodents, inclusive
of appropriate electrocardiographic measurements in nonrodents
(26, 27). The design of toxicology or biodistribution studies in
rodents and nonrodents should also assess radioactivity
cytotoxicity effect size in vital normal organs. Because of the
bone-homing characteristic, hematopoietic deficits resulting
from marrow stem cell ablation were an adverse event of special
interest in the in vivo evaluation of Sn-117m-DTPA (9, 10).
Thus, our step 2 validation process is more laborious, time
intensive, and expensive than step 1. But it uses time-honored
preclinical in vitro and in vivo experiments to justify early-phase
trials, as has been requested before (20). In our opinion, step 2
offers very strong credentials for evidence indicating benefits of
treatment in a radiopharmaceutical-specific subpopulation.
Recommendation Step 3
An oncology therapeutic radiopharmaceutical used in patients
with cancer to treat the disease or palliate tumor-related
symptoms should first demonstrate uptake by the tumor and
avoid uptake by vital organs in a single animal model species.
Radiation/nuclear medicine follows the lead of the U.S. Food
& Drug Administration (FDA) and classifies medical imaging or
biological products into at least three categories—contrast
agents, diagnostic radiopharmaceuticals, and oncology
therapeutic radiopharmaceuticals (26, 27). An image contrast
agent is one used to enhance the visualization of tissues, organs,
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or physiologic processes by increasing the relative intensity of
imaging signals in side-by-side body regions. A diagnostic
radiopharmaceutical is an agent used in the diagnosis or
monitoring of a disease, and, has a radionuclide that decays with
an emission of detectable nuclear particles or photons typically
linked to a nonradioactive targeting ligand or radiochemical
carrier. Such agents are used in nuclear medicine procedures
like planar imaging single photon emission computed
tomography (SPECT), positron emission tomography (PET), or
in combination with other emitted radiation detectors. A
therapeutic radiopharmaceutical is usually a ligand- or
radiochemical-chelated radionuclide used in the treatment of a
disease or in the palliation of disease-related symptoms (e.g., pain).
Such agents are used in radiation medicine/oncology treatments.
The term “theranostic radiopharmaceutical” means the same
nonradioactive targeting ligand or radiochemical chelator carries
either i) a diagnostic radionuclide to assess tumor uptake and any
spread of cancer elsewhere in the body, or ii) a therapeutic
radionuclide as treatment (28). We forecast that next generation
radiopharmaceuticals likely will bear both a diagnostic and a
therapeutic radionuclide at the same time. Step 3 in our process
first involves showing oncology therapeutic radiopharmaceutical
uptake by the tumor and avoidance of vital organs in a single
animal species (Figure 1).
Standardized radiation/nuclear medicine practice evaluates
post-administration radioactivity in organs over time intervals
(like 5 × the effective half-life). This creates time-integrated
activity curves. Organs measured for time-integrated activity
include the adrenal glands, bone and bone marrow, brain,
small and large intestine walls, stomach, heart, kidneys, liver,
lungs, muscles, ovaries, pancreas, spleen, testes, thymus, thyroid,
urinary bladder, uterus, and total body (26, 27). Tabular data for
absorbed dose estimates should be reported, as has been done for
Sn-117m-DTPA (12). Radioactivity in urine and in feces should
be recorded for elimination pharmacokinetic assessments. If
adequately justified, the number of organs evaluated might be
abbreviated to include bone marrow and organs of excretion,
such as kidneys and liver, due to these organs being exposed
regardless of target binding. An example of using a limited
biodistribution organ list is when demonstrating comparability
of two related oncology therapeutic radiopharmaceuticals
(bridging study) such as a switch from a low-specific activity to
high-specific-activity product like is planned for Sn-117m-
DTPA. In our view, the experimental design of an animal
biodistribution study should integrate, when possible, medical
components of any planned early-phase human biodistribution
and dosimetry study, as these medical components might affect
the eventual distribution of a radiopharmaceutical product.
A B C
FIGURE 2 | Radiopharmaceutical-drug screen for in vivo cytotoxic effect size using zebrafish (Danio rerio). (A) Listed are at least eight of the possible treatment
schemes for a three-agent oncology therapeutic drug screen. To test each treatment in higher order vertebrates (like 40 mice) would be expensive, and, an up to 3-
month endeavor. Oppositely, to test each treatment in zebrafish (like 12 fish per treatment from a single 100-embryo clutch) is inexpensive, robust, and finishes in 14
days or less. (B) Depicted are basic developmental milestones for zebrafish postfertilization, from embryo to larvae (72 h) to juvenile fish (14 days). Unperturbed
zebrafish development is linear. Treatment (arrows) stalls maturation versus time, with greater treatment effect proportional to protracted growth and maturation.
Teratogenic treatment effects are also readily apparent. (C) Zebrafish-screened “effective” treatments are carried forward to conventional, reduced total animal
number, rodent or nonrodent tumor growth delay assays.
Kunos et al. Radiopharmaceutical Validation
Frontiers in Oncology | www.frontiersin.org March 2021 | Volume 11 | Article 6308275
For example, if a planned early-phase clinical trial allows patients
being pretreated by bone health agents (e.g., zoledronic acid or
denosumab) to enroll, then the use of bone health agents should
be considered in the animal biodistribution study. This
consideration is often omitted in favor of simple and efficient
single dose animal imaging study in a single species (26, 27).
In our view, step 3 determines whether there are any body
sites in which the radioactive drug particularly concentrates, or,
in which the radioactive drug predominantly excludes. In our
opinion, step 3 ties together the preclinical data from step 1 and
step 2 into a programmatic platform sufficient to test a new
oncologic therapeutic radiopharmaceutical in a subgroup of
“theranostic-positive” patients (Figures 3, 4). This step will
provide an estimate of radiation doses that could be delivered
to the tumor without exceeding the maximum safe doses to
normal tissues.
Recommendation Step 4
An oncology therapeutic radiopharmaceutical used in patients
with cancer to treat the disease or palliate tumor-related
symptoms should demonstrate uptake by the tumor and avoid
uptake by vital organs in a first-in-human microdose study.
A
B
FIGURE 3 | Radiopharmaceutical target-driven early-phase enrichment trial designs. (A) Early-phase 0 enrichment trial designs evaluate a new treatment only in a
theranostic target-positive subject subpopulation. (B) Early-phase I trial designs for agent safety as a primary objective in an ‘all-comer’ approach might otherwise
assign both target-positive and target-negative patients to a radiopharmaceutical treatment under investigation. Diagnostic imaging means baseline and posttherapy
conventional radiation/nuclear medicine imaging for initial exploratory objective response assessment in either trial design.
A B
FIGURE 4 | Radiopharmaceutical target-driven phase II combination trial designs isolating treatment effects. (A) Enrichment phase II trial designs
evaluate a diagnostic agent in a theranostic pair as a triage step in all patients. Random allocation applies only to patients with “theranostic-positive”
results. (B) Theranostic pair-stratified designs randomly allocate both “theranostic-positive” and “theranostic-negative” patients to the radiopharmaceutical-
based treatment under investigation. Diagnostic imaging means baseline and posttherapy conventional radiation/nuclear medicine imaging for objective
response assessments.
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Our fourth recommended validation step provides visual and
physical evidence, in a conventional first-in-human microdose
study, that a possible oncology therapeutic radiopharmaceutical
demonstrates uptake by the tumor and avoids uptake by vital
organs. Currently, the microdose study can be conducted under
an Exploratory Investigational New Drug (xIND) application, as
outlined in a 2006 FDA guidance (29). In these first-in-human
studies, very small single doses (e.g., 1/100th) of an agent are
administered for medical imaging assessment, and therefore, the
hazard for toxicity is rare. We argue that a conventional
microdose study informs the evaluation of oncology
therapeutic radiopharmaceuticals by providing more data on
human i) biological effects, ii) starting doses, and iii) schedules.
Microdose studies are an important precursor to phase 0 or
phase I trial design in that they might inform patient selection or
biospecimen sampling strategies (Table 1).
Step 4 in our view uses the same ratio of nonradioactive-to-
radioactive components that was used in the step 3 single animal
species study. Following our example, the low-specific-activity
Sn-117m-DTPA has a 20-fold molar excess of the acid salt of
DTPA over radioactive Sn-117m (12). The same 20:1 low-
specific-activity product that was given in rodent and
nonrodent SPECT biodistribution studies was given in a first-
in-human anterior-posterior single-pass 18-min whole-body
SPECT scan (10 cm/min with matrix 1024 x 512). Sn-117m-
DTPA human bone activity was about constant over a 196-h
observation period; Sn-117m-DTPA blood activity nearly
completely disappeared in the first 15 min post-administration
(12). Sn-117m-DTPA SPECT images were comparable to Tc-
99m-methyl diphosphonate (MDP) scintigrams (12). Such
pharmacokinetic and pharmacotoxic data inform next step
trials (Figures 3, 4). Microdose study data inform “theranostic
triage” for trial enrichment, whereby a positive imaging study
(e.g., SPECT) assigns trial-specific treatment rather than to all.
Phase II trials utilize enrichment by selecting only theranostic
triage-positive patients, and then, randomizing trial-specific or
standard treatment.
Step 4 provides clinical experience upon which other early-phase
trials of an oncology therapeutic radiopharmaceutical test safety and
efficacy. It will also verify the estimate of radiation doses that could
be delivered to the tumor without exceeding the maximum safe
doses to normal tissues from step 3. In many clinical scenarios, step
4 microdose studies have been done at the outset of the drug-
development sequence. However, we strongly encourage
progressing through steps 1 to 4 in sequence as the overall
process provides the best justifications for human trials as well as




Certain new therapeutic radiopharmaceuticals like high-specific
activity Sn-117m-DTPA use radionuclides in drug products that
are not yet approved for clinical use by the FDA. In this case,
there has been a discussion of the usefulness of modular drug
master files (DMF) that draw upon components of other FDA-
filed DMFs for radiochemistry, manufacturing, and control
processes (30). This ensures patient safety and speeds up IND-
enabling studies that justify early-phase trials.
In the current early-phase operationalization process for
radiopharmaceutical IND-sponsored trials, trial sites must submit
their radioactive materials license (RML) on a per study basis to
indicate its authority to handle a specific radionuclide drug product
for medical use, as guided by the Nuclear Regulatory Commission
(NRC) and applicable agreement state regulations. The site’s RML
(updated as needed for new radionuclide authorizations, authorized
users, or license expirations) is used by CTEP to credential the trial
site as a targeted radiopharmaceutical facility organization (TRF).
Sites desiring to enroll patients to CTEP-sponsored
radiopharmaceutical trials must align themselves with their TRF
via the Clinical Trials Support Unit (CTSU) regulatory provider
association function. An attestation that the site uses a valid
calibrated dose calibrator for measuring the relevant isotope
radioactivity is a necessity. A list of all authorized users of a
specific radionuclide under clinical investigation must be provided
to CTEP and verified against the site RML for authorized user
credentialing (inclusive of nuclear medicine and radiation oncology
physicians, radiation or nuclear medicine physicists, technicians, or
radiopharmacists involved in prescribing, receipt, storage, handling,
preparation, dispensing, and treatment of study patients with
radiopharmaceuticals). Depending on the radiopharmaceutical
under investigation, radionuclide-specific training on safe
handling and clinical use must be documented either by the RML
or radionuclide training certificate verified by CTEP. To illustrate
these points, take the training requirement for handling Sn-117m-
DTPA. Training is not required by U.S. Federal law or FDA
regulation, but the knowledge and experience gained by site
TABLE 1 | Microdose study elements that inform radiopharmaceutical phase 1 or phase 0 trials.
Microdose Study Element Phase 1 trial design impact Phase 0 trial design impact
Primary biodistribution endpoint Sets dosage recommended for phase 1 study Sets dosage providing target modulation
Biomarker assay Adds exploratory pharmacodynamic assay Adds integral pharmacodynamic endpoint
Bioimaging or dosimetry Adds exploratory pharmacodynamic assay Adds integrated pharmacodynamic endpoint
Dose dilution sub-study Identifies CTCAE toxicity of special interest Sets dosage for desired target modulation
Dose administration Rationalizes multiple cycle administration Justifies single cycle administration
Single species safety evaluation Rationalizes 15–18 patient study Justifies 8–10 subject study
Pharmacokinetics Provides batched blood sampling frequency Provides real-time blood sampling frequency
CTCAE, Common Terminology Criteria for Adverse Events (current version).
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authorized users on safe handling and clinical use is a state
regulation. It is also good clinical practice. We anticipate such
training to be documented at each trial site before any accrual to an
early-phase trial of Sn-117m-DTPA.
Another key aspect for radiopharmaceutical CTEP IND-
sponsored trials tracks investigator and sub-investigator trial
tasks on the clinical trial delegation of tasks log (DTL). New
task assignments for radiopharmaceuticals are required on a
CTEP IND-sponsored trial DTL. First, the DTL must list two or
more authorized user physician prescribers for the
radiopharmaceutical as identified by the clinical trial site’s RML
or Radiation Safety Officer (RSO) approved list. Second, the DTL
must identify at least two trained and authorized persons for the
task of receipt, storage, handling, preparation, dispensing and final
disposition of the radiopharmaceutical (again as identified by the
clinical trial site’s RML or RSO approved list). Any other sub-
investigators involved in the clinical investigation (both authorized
users for medical use and other site trained personnel) must also
be identified on the site DTL. CTEP intends to work on ways to
facilitate the site and investigator/sub-investigator credentialing
process for radiopharmaceutical trials, to eventually reduce any
duplicity in the credentialing process across clinical investigations.
Further effort in enhancing collection of site credentials and
authorized personnel site rosters is needed.
CONCLUSION
In summary, this article explores elements in radiopharmaceutical
validation for clinical use as they relate to the justification of
early-phase clinical trials. It sharpens thinking about the levels of
evidence used to predict radiopharmaceutical therapeutic success
through a discussion of trial-enabling immunohistochemistry,
preclinical in vitro or in vivo experiments, biodistribution and
dosimetry studies, as well as first-in-human experience.
Education on the operationalizing of radiopharmaceutical trials
for authorized users and their support staff remains essential for
the favorable development of these forms of cancer treatment.
Delegation of task logs are key elements in the responsible
conduct of early-phase radiopharmaceutical trials for
therapeutic intent.
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